Dr Juan A. Fernández General Hospital, CABA, Argentina.
Laboratory of Experimental Thrombosis, Institute of Experimental Medicine-CONICET, National Academy of Medicine, CABA, Argentina.
Haemophilia. 2020 Jul;26(4):e187-e193. doi: 10.1111/hae.14075. Epub 2020 Jun 12.
Haemarthroses cause major morbidity in haemophilia resulting in chronic haemophilic synovitis (CHS) and arthropathy. Oxidation of haemoglobin-coupled iron released in synovium after haemolysis induces chondrocytes death and cartilage damage, allowing postulate using iron-chelating drugs as potential therapeutic tool for haemophilic joint damage. Considering that albumin, the most abundant plasma protein, is a physiologic iron chelator, we aim to demonstrate that impediment of haemoglobin oxidation is exerted by plasma as a mechanism involved in the therapeutic effect of intra-articular injection of platelet-rich plasma in CHS.
Oxidation of haemoglobin (Hb) to methaemoglobin (MeHb) through Fenton reaction was induced in vitro by addition of potassium ferricyanide in the presence or absence of peripheral blood-derived platelets-rich or platelets-poor plasma (PRP/PPP) or albumin. The relevance of in vitro findings was analysed in synovial fluid (SF) samples from one patient with CHS obtained before and after 6 months of PRP intra-articular injection.
MeHb formation was completely impaired either by of PPP, PRP or albumin indicating that PRP exerts an anti-oxidative effect, probably due by plasma albumin. Analysis of SF samples revealed the presence of MeHb levels and haemosiderin-laden macrophages in SF obtained before PRP treatment. Reduction of synovial MeHb, normalization of cellular composition and improvement of health joint haemophilic score, pain and bleeding episodes were registered after 6 months of PRP intra-articular injection.
Inhibition of Fenton reaction and the consequent normalization of joint cellular composition is a noncanonical mechanism underlying the therapeutic effect of PRP intra-articular injection in CHS.
血友病患者发生关节积血可导致严重的发病率,引起慢性血友病性滑膜炎(CHS)和关节病。溶血后释放到滑膜中的血红蛋白结合铁的氧化诱导软骨细胞死亡和软骨损伤,这使得使用铁螯合剂作为潜在的血友病性关节损伤治疗工具的假设成立。考虑到白蛋白是最丰富的血浆蛋白,是一种生理性铁螯合剂,我们旨在证明,作为关节内注射富含血小板血浆治疗 CHS 疗效相关机制,阻止血红蛋白氧化是由血浆发挥作用的。
通过在存在或不存在外周血富血小板或贫血小板血浆(PRP/PPP)或白蛋白的情况下添加铁氰化钾,在体外诱导血红蛋白(Hb)通过 Fenton 反应氧化为高铁血红蛋白(MeHb)。分析了一名 CHS 患者关节滑液(SF)样本中的体外发现的相关性,该患者在接受 PRP 关节内注射 6 个月前后获得了 SF 样本。
PPP、PRP 或白蛋白完全抑制了 MeHb 的形成,表明 PRP 发挥了抗氧化作用,可能是由于血浆白蛋白的作用。SF 样本分析显示,在 PRP 治疗前的 SF 样本中存在 MeHb 水平和含铁血黄素的巨噬细胞。在接受 PRP 关节内注射 6 个月后,观察到滑膜 MeHb 减少、细胞成分正常化以及血友病性关节健康评分、疼痛和出血发作改善。
Fenton 反应的抑制和关节细胞成分的随之正常化是 PRP 关节内注射治疗 CHS 疗效的非经典机制。